Successful treatment of hemophagocytic intravascular large B-cell lymphoma with CNS involvement with BTK inhibitor combined with rituximab and high-dose methotrexate

被引：0
|
作者：
Shao, Fangfei [2 ,4 ]
Su, Wei [1 ]
Zhao, Xiujie [2 ]
He, Jianping [5 ]
Wang, Xiaofen [6 ]
Guo, Feng [1 ]
Xiao, Haowen [2 ,3 ]
机构：
[1] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Intens Care Unit, 3 Qingchun East Rd, Hangzhou 310018, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Hematol & Cell Therapy, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Inst Hematol, Hangzhou 310018, Zhejiang, Peoples R China
[4] Zhejiang Univ, Shaoxing Shangyu Hosp Tradit Chinese Med, Sir Run Run Shaw Hosp, Dept Hematol & Cell Therapy,Shaoxing Branch,Sch Me, Hangzhou, Zhejiang, Peoples R China
[5] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Dermatol, Hangzhou, Zhejiang, Peoples R China
[6] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Clin Lab, Hangzhou, Zhejiang, Peoples R China
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2024年 / 15卷
基金：
中国国家自然科学基金;
关键词：
BTK inhibitor; CNS involvement; hemophagocytic syndrome; intravascular large B-cell lymphoma; NF-kappa B pathway; MANAGEMENT;
D O I：
10.1177/20406207241270788
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This is a case of hemophagocytic intravascular large B-cell lymphoma (IVLBCL) with central nervous system (CNS) involvement. Although R-CHOP chemotherapy regimen has been shown significant improvement in survival rate. The prognosis and outcomes remain unsatisfactory, which is identified as outstanding challenges and need solutions. Gene and molecular profiling studies may provide new therapeutic strategies, especially the BCR/TLR/IL-1R/NF-kappa B signaling pathway in IVLBCL. Here, we treated the hemophagocytic IVLBCL CNS-involved patient with the Bruton tyrosine kinase inhibitor (BTKi) to block NF-kappa B pathway, and indicated that the second-generation BTKi zanubrutinib-based treatment was feasible and efficient.
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Successful treatment of cutaneous intravascular large B-cell lymphoma with fludarabine phosphate
    Shan, Shi-Jun
    Chen, John
    Geng, Shi-Ling
    Hong, Yuxiao
    Xu, Honghui
    Guo, Ying
    Wei, Huachen
    Zhai, Ming
    Chen, Hong-Duo
    EUROPEAN JOURNAL OF DERMATOLOGY, 2010, 20 (03) : 408 - 409
  • [32] ALTERNATING HIGH-DOSE METHOTREXATE WITHIN R-CHOP21 IS FEASIBLE IN AGGRESSIVE B-CELL LYMPHOMA PATIENTS AT RISK FOR CNS INVOLVEMENT
    Kim, T. D.
    Nogai, H.
    Daebritz, J. M.
    Schmitt, C. A.
    Doerken, B.
    Pezzutto, A.
    ANNALS OF ONCOLOGY, 2011, 22 : 194 - 194
  • [33] Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma
    Akimoto, Masahiro
    Miyazaki, Takuya
    Takahashi, Hiroyuki
    Takeda, Takaaki
    Hibino, Yuto
    Tokunaga, Mayumi
    Ohashi, Takuma
    Matsumura, Ayako
    Teshigawara, Haruka
    Suzuki, Taisei
    Teranaka, Hiroshi
    Nakajima, Yuki
    Matsumoto, Kenji
    Hashimoto, Chizuko
    Fujimaki, Katsumichi
    Fujita, Hiroyuki
    Sakai, Rika
    Fujisawa, Shin
    Nakajima, Hideaki
    INTERNAL MEDICINE, 2025,
  • [34] Rituximab with High Dose Methotrexate in the Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
    Kansara, Roopesh R.
    Shenkier, Tamara
    Connors, Joseph M.
    Gerrie, Alina S.
    Klasa, Richard
    Savage, Kerry J.
    Sehn, Laurie H.
    Villa, Diego
    BLOOD, 2014, 124 (21)
  • [35] The Efficacy of High-Dose Versus Intrathecal Methotrexate for Diffuse Large B-Cell Lymphoma with High Risk of CNS Relapse: A Multicenter Retrospective Study with Uniform CNS Prophylaxis
    Akimoto, Masahiro
    Miyazaki, Takuya
    Takahashi, Hiroyuki
    Saigusa, Yusuke
    Takeda, Takaaki
    Hibino, Yuto
    Tokunaga, Mayumi
    Ohashi, Takuma
    Matsumura, Ayako
    Teshigawara, Haruka
    Suzuki, Taisei
    Teranaka, Hiroshi
    Nakajima, Yuki
    Matsumoto, Kenji
    Hashimoto, Chizuko
    Fujimaki, Katsumichi
    Fujita, Hiroyuki
    Sakai, Rika
    Fujisawa, Shin
    Nakajima, Hideaki
    BLOOD, 2022, 140 : 3809 - 3810
  • [36] Addition of High-Dose Methotrexate to Initial Chemotherapy Improved Treatment Outcome of Patients with Newly Diagnosed Intravascular Large B-Cell Lymphoma: A Multicenter, Retrospective Study
    Harada, Shinpei
    Goto, Hideki
    Senjo, Hajime
    Suto, Keito
    Izumiyama, Koh
    Yamamoto, Masayo
    Sato, Kazuya
    Kakinoki, Yasutaka
    Saga, Tomoyuki
    Shigematsu, Akio
    Horiguchi, Hiroto
    Takahata, Mutsumi
    Ogasawara, Reiki
    Yamamoto, Satoshi
    Yamaguchi, Keisuke
    Wakasa, Kentaro
    Igarashi, Tetsuyuki
    Haseyama, Yoshihito
    Ito, Shinichi
    Fujimoto, Katsuya
    Hashiguchi, Junichi
    Nakagawa, Masao
    Hashimoto, Daigo
    Teshima, Takanori
    BLOOD, 2023, 142
  • [37] Pituitary Gland and Neurological Involvement in a Case of Hemophagocytic Syndrome Revealing an Intravascular Large B-Cell Lymphoma
    Njonnou, Sylvain Raoul Simeni
    Couturier, Bruno
    Gombeir, Yannick
    Verbanck, Sylvain
    Devuyst, France
    El Hachem, Georges
    Theate, Ivan
    Trepant, Anne-Laure
    De Wilde, Virginie
    Vandergheynst, Frederic-Alain
    CASE REPORTS IN HEMATOLOGY, 2019,
  • [38] High-Dose Methotrexate, Rituximab, and Temozolomide (MRT) for Patients with Primary CNS Lymphoma (PCNSL).
    Gerstner, Elizabeth R.
    Hochberg, Fred H.
    Plotkin, Scott R.
    Eichler, April F.
    Batchelor, Tracy T.
    BLOOD, 2009, 114 (22) : 667 - 667
  • [39] Comparison of different neuromeningeal prophylaxis strategies with high-dose methotrexate in diffuse large B-cell lymphoma
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (03): : 176 - 177
  • [40] PRIMARY CNS LYMPHOMA TREATED WITH HIGH-DOSE METHOTREXATE AND RITUXIMAB - SINGLE INSTITUTION EXPERIENCE
    Mrugala, M. M.
    Crew, L. K.
    NEURO-ONCOLOGY, 2012, 14 : 84 - 84
12345